AI Article Synopsis
Article Abstract
Introduction: Mutations of hepatitis B virus (HBV) polymerase, especially occurring at the highly conserved YMDD region, are related to resistance to lamivudine. Although these mutations are frequently secondary to lamivudine use, they can also occur naturally. The aim of the present study was to determine the prevalence of YMDD variants that exist naturally in patients who are inactive HBV carriers.
Methods: Seventy-one adult inactive HBV carriers were studied. All of the patients were confirmed to have maintained normal alanine aminotransferase (ALT) values for one or more years by monitoring serum ALT levels at 3-monthly intervals. None of the patients received interferon or antiviral agents. YMDD variants were analyzed by the HBV Drug Resistance Line Probe assay (Inno-Lipa HBV-DR).
Results: YMDD variants were detected in 13 (18.3%) of the 71 anti-HBe positive inactive HBV carriers. Of the 13 patients, 10 (76.9%) also had accompanying L180M mutation. The combination of wild type and YMDD variant HBV was present in 11 of 13 patients. In two patients, only YIDD and/or YVDD variants plus L180M were detected without the presence of wild YMDD motif.
Conclusion: Naturally occurring YMDD motif variants were detected at a high rate in a group of lamivudine-untreated inactive HBV carriers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1440-1746.2006.04567.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The host gene regulates HBV replication via HBV PRE-induced nuclear export.
Acta Biochim Biophys Sin (Shanghai)
December 2024
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
The persistent global burden of hepatitis B virus (HBV) infection has prompted ongoing investigations into host determinants of viral control. In this study, we investigate the regulatory influence of the host gene cleavage stimulation factor subunit 2 (CSTF2) on HBV replication dynamics. We demonstrate differential CSTF2 expression across the spectrum of HBV infection phases, with upregulated expression noted during the immune-reactive and inactive carrier states compared with the immune-tolerant phase.
View Article and Find Full Text PDFComparison of Basal Core Promoter Region Mutation and Precore Mutation among Monoinfected Hepatitis B Virus and Coinfected Hepatitis B Virus with Human Immunodeficiency Virus Patients.
J Assoc Physicians India
December 2024
Assistant Professor, Department of Microbiology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India, Corresponding Author.
Objectives: Hepatitis B virus (HBV) has a partially double-stranded circular deoxyribonucleic acid (DNA) that replicates through reverse transcription, producing an intermediate ribonucleic acid (RNA). This replication process has a high chance of error, leading to several mutations in the genome. According to several studies conducted worldwide, the classical basal core promoter (BCP) double mutation (A to T at nucleotide 1762 and G to A at nucleotide 1764) in the BCP region and the mutation in the precore (PC) region (G to A at nucleotide 1896) of HBV DNA have a strong correlation with advanced liver disease.
View Article and Find Full Text PDFMonocyte-derived Galectin-9 and PD-L1 differentially impair adaptive and innate immune response in chronic HBV infection and their expression remain unaltered after antiviral therapy.
Front Immunol
October 2024
Centre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Introduction: Patients with chronic HBV infection (CHI) exhibit defective anti-viral immune-response whose underlying causes still remain unclear. Monocytes act as immune sentinels for pathogens and can regulate immunity via interaction with other immune-cells, apart from differentiating into macrophages. Immune-checkpoint molecules (ICMs) expressed by immune-cells, including monocytes are known to negatively regulate immune-responses.
View Article and Find Full Text PDFNucleos(t)ide analogs to treat patients with positive hepatitis B virus deoxyribonucleic acid and normal alanine transaminase: protocol for an open-label single-center randomized parallel controlled trial.
Trials
October 2024
Center of Infectious Diseases, West China Hospital, Sichuan University, No.37 Guo Xue Xiang, Wuhou District, Chengdu, 610041, China.
Background: Direct high-quality evidence remains absent on the benefits of HBeAg-negative chronic hepatitis B patients (CHB) with normal alanine transaminase (ALT) and positive HBV DNA after nucleos(t)ide analogs (NAs) treatment.
Methods: This is a single-center, open-label, randomized parallel controlled trial with a follow-up duration of 96 weeks. An estimated 300 patients will be recruited at West China Hospital of Sichuan University, China.
Histological Findings in Antigen E Positive and Negative in Chronic Hepatitis B.
J Coll Physicians Surg Pak
August 2024
Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital, Diyarbakir, Turkiye.
Objective: To determine the histopathological findings in patients with HBeAg-positive chronic HBV infection (immunotolerant phase in old terminology) and HBeAg-negative chronic HBV infection (inactive carrier phase in old terminology).
Study Design: Observational study. Place and Duration of the Study: Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital, Diyarbakir, Turkiye and Diyarbakir and Mersin University School of Medicine, Diyarbakir, Turkiye, from May 2014 to August 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!